ログイン
ランキング
お知らせ
ログイン
文献詳細
増大特集 大脳皮質vs.大脳白質
文献概要
初老期から老年期には多くの疾患ないし病態が認知症を呈する。本稿では，皮質性認知症の2大原因疾患であるアルツハイマー病と前頭側頭葉変性症について，その疾患概念の歴史的変遷，病理や画像所見を含めた診断的特徴，大脳皮質の局在認知機能からみた臨床症状と最近のトピックスについて概説した。
参考文献
1) 高橋三郎, 染矢俊幸, 大野 裕（訳): DSM-IV-TR精神疾患の診断・統計マニュアル. 医学書院, 東京, 2003
2) Alzheimer A: Ueber eine eigenartige Erkrankung der Himrinde. Allg Z Psychiat Med 64: 146-148, 1907
3) Braak H, Braak E: Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82: 239-259, 1991
4) Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR: Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 10: 122-126, 1981
5) Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, et al: Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 215: 1237-1239, 1982
6) 下濱 俊: アルツハイマー病の治療——現状と解決すべき諸問題. 日薬理誌131: 351-356, 2008
7) Hardy JA, Higgins GA: Alzheimer's disease: the amyloid cascade hypothesis. Science 256: 184-185, 1992
8) 川又 淳: アルツハイマー型認知症——臨床で必要となる基本事項. 中島健二, 天野直二, 下濱 俊, 冨本秀和, 三村 将（編): 認知症ハンドブック, 医学書院, 東京, 2013, pp492-504
9) Tomiyama T, Nagata T, Shimada H, Teraoka R, Fukushima A, et al: A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia. Ann Neurol 63: 377-387, 2008
10) Hutton M, Lendon, CL, Rizzu P, Baker M, Froelich S, et al: Association of missense and 5-prime-splice-site mutations in tau with the inherited dementia FTDP-17．Nature 393: 702-705, 1998
11) Jack CR Jr, Albert MS, Knopman DS, McKhann GM, Sperling RA, et al: Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 257-262, 2011
12) McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, et al: The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 263-269, 2011
13) McKhann G, Drachman D, Folstein M, Katzman R, Price D, et al: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-944, 1984
14) Han SD, Gruhl J, Beckett L, Dodge HH, Stricker NH, et al: Beta amyloid, tau, neuroimaging, and cognition: sequence modeling of biomarkers for Alzheimer's Disease. Brain Imaging Behav 6: 610-620, 2012
15) Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, et al: The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement 8(1 Suppl): S1-S68, 2012
16) Hampel H, Bürger K, Teipel SJ, Bokde AL, Zetterberg H, et al: Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement 4: 38-48, 2008
C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 131(Pt 3): 665-680, 2008
18) Chételat G, Villemagne VL, Bourgeat P, Pike KE, Jones G, et al: Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol 67: 317-324, 2010
19) Sperling RA, Aisen PS, Beckett LA, Bennett LA, Craft S, et al: Toward the preclinical stages of Alzheimer's disease: recommendation from the National Institute on Aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 280-292, 2011
20) Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, et al: The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendation from the National Institute on Aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 270-279, 2011
21) 齊藤正樹: アルツハイマー型認知症——臨床症状. 中島健二, 天野直二, 下濱 俊, 冨本秀和, 三村 将（編): 認知症ハンドブック. 医学書院, 東京, 2013, pp514-520
22) Hirono N, Mori E, Tanimukai S, Kazui H, Hashimoto M, et al: Distinctive neurobehavioral features among neurodegenerative dementias. J Neuropsychiatry Clin Neurosci 11: 498-503, 1999
23) Lee GJ, Lu PH, Hua X, Lee S, Wu S, et al; Alzheimer's Disease Neuroimaging Initiative: Depressive symptoms in mild cognitive impairment predict greater atrophy in Alzheimer's disease-related regions. Biol Psychiatry 71: 814-821, 2012
24) de Souza LC, Lamari F, Belliard S, Jardel C, Houillier C, et al: Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias. J Neurol Neurosurg Psychiatry 83: 695-698, 2011
25) Kas A, Uspenskaya O, Lamari F, de Souza LC, Habert MO, et al: Distinct brin perfusion pettern associated with CSF biomarkers profile in primary progressive aphasia. J Neurol Neurosurg Psychiatry 83: 695-698, 2012
26) Benson DF, Davis Rj, Snyder BD: Posterior cortical atrophy. Arch Neurol 45: 789-793, 1988
27) Seguin J, Formaglio M, Perret-Liaudet A, Quadrio I, Tholance Y, et al: CSF biomarkers in posterior cortical atrophy. Neurology 76: 1782-1788, 2011
28) Crutch SJ, Lehmann M, Warren JD, Rohrer JD: The language profile of posterior cortical atrophy. J Neurol Neurosurg Psychiatry 84: 460-466, 2013
29) Tang-Wai DF, Graff-Radford NR, Boeve BF, Dickson DW, Parisi JE, et al: Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology 63: 1168-1174, 2004
30) Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, et al: Classification of primary progressive aphasia and its variants. Neurology 76: 1006-1014, 2011
31) Braak H, Braak E: Argyrophilic grains: characteristic pathology of cerebral cortex in cases of adult onset dementia without Alzheimer changes. Neurosci Lett 76: 124-127, 1987
32) Togo T, Sahara N, Yen SH, Cookson N, Ishizawa T, et al: Argyrophilic grain disease is a sporadic 4-repeat tauopathy. J Neuropathol Exp Neurol 61: 547-556, 2002
33) Adachi T, Saito Y, Hatsuta H, Funabe S, Tokumaru AM, et al: Neuropathological asymmetry in argyrophilic grain disease. J Neuropathol Exp Neurol 69: 737-744, 2010
34) Yamada M: Senile dementia of the neurofibrillary tangle type (tangle-only dementia): neuropathological criteria and clinical guidelines for diagnosis. Neuropathology 23: 311-317, 2003
35) 島田 斉, 丸山将浩, 樋口真人, 須原哲也: 認知症診断におけるtau, amyloid imagingの役割. 臨床画像30: 177-186, 2014
36) Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, et al: Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 132: 1355-1365, 2009
37) Chetelat G, Villemagne VL, Villain N, Jones G, Ellis KA, et al: Accelerated cortical atrophy in cognitively normal elderly with high β-amyloid deposition. Neurology 78: 477-484, 2012
38) Sperling RA, Laviolette PS, O'Keefe K, O'Brien J, Rentz DM, et al: Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron 63: 178-188, 2009
39) Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, et al: Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Alzheimers Dement 9: e1-e16, 2013
40) Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, et al: Imaging of tau pathology in a tauopathy mouse and in Alzheimer patients compared to normal controls. Neuron 79: 1094-1108, 2013
F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med 54: 1420-1427, 2013
42) Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, et al: Early clinical PET imaging results with the novel PHF-tau radioligand ［F-18］-T807．J Alzheimers Dis 34: 457-468, 2013
43) Raichle ME, MacLeod AM, Snyder AZ, Powers WJ, Gusnard DA, et al: A default mode of brain function. Proc Natl Acad Sci U S A 98: 676-682, 2001
44) Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, et al: Metabolic reduction in the posterior cingulated cortex in very early Alzheimer's disease. Ann Neurol 42: 85-94, 1997
45) Lustig C, Snyder AZ, Bhakta M, O'Brien KC, McAvoy M, et al: Functional deactivations: change with age and dementia of the Alzheimer type. Proc Natl Acad Sci U S A 100: 14504-14509, 2003
46) Sorg C, Riedl V, Mühlau M, Calhoun VD, Eichele T, et al: Selective changes of resting-state networks in individuals at risk for Alzheimer's disease progression. Proc Natl Acad Sci U S A 104: 18760-18765, 2007
47) Zhou J, Greicius MD, Gennatas ED, Growdon ME, Jang JY, et al: Divergent network connectivity changes in behavioral variant frontotemporal dementia and Alzheimer's disease. Brain 133: 1352-1367, 2010
48) Filippi M, Agosta F, Scola E, Canu E, Magnani G, et al: Functional network connectivity in the behavioral variant frontotemporal dementia. Cortex 49: 2389-2401, 2013
49) 林 俊宏: Default mode network——認知症の観点から. 臨床画像30: 187-197, 2014
50) Gustafson L. Frontal lobe degeneration of non-Alzheimer type. II. clinical picture and differential diagnosis. Arch Gerontol Geriatr 6: 209-223, 1987
51) Neary D, Snowden JS, Northen B, Goulding P: Dementia of frontal lobe type. J Neurol Neurosurg Psychiatry 51: 353-361, 1988
52) Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, et al: Frontotemporal lobar degeneration: aconsensus on clinical diagnostic criteria. Neurology 51: 1546-1554, 1998
53) 松村晃寛, 山内理香, 下濱 俊: 認知症の鑑別診断——AD, VaD, DLB, FTLD. 治療89: 2972-2978, 2007
54) Mackenzie IR, Neumann M, Baborie A, Sampathu DM, Du Plessis D, et al: A haramonized classification system for FTLD-TDP pathology. Acta Neuropathol 122: 111-113, 2011
55) Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, et al: TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 351: 602-611, 2006
56) Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, et al: Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314: 130-133, 2006
掲載誌情報
